Nordea is a bit dissapointed with Novo’s guidance
Novo Nordisk has presented another strong interim report for its third quarter, but future prospects are a bit disappointing, says pan-Nordic bank Nordea - and it looks like the market feels the same way about it.
BY BENJAMIN WERNER CHRISTENSEN
It is chutes and ladders in Thursday’s interim report from the pharmaceutical group Novo Nordisk, says pan-Nordic bank Nordea.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
US specialist investors underestimate Tresiba
For abonnenter
Novo targets workers from Germany and Poland
For abonnenter
